OTC · Biotechnology

Ascentage Pharma Group International (AAPGV) Stock

$17.38 +0.75% OTC: AAPGV Healthcare

Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapeutic solutions for various cancers, chronic hepatitis B virus (HBV) infection, and age-related conditions, primarily within Mainland China. Its flagship product candidate, HQP1351, is a BCR-ABL inhibitor specifically designed to target BCR-ABL1 mutants, notably those harboring the T315I mutation.

Valuation

MetricValue
Price$17.38
Market Cap$127.31M
P/E Ratio-9.87
P/B Ratio9.54
P/S Ratio22.36
EPS (TTM)$-1.34
52-Week High$18.00
52-Week Low$16.50
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-123.61%
ROA-31.03%
ROCE-51.46%
Gross Margin84.09%
Operating Margin-210.42%
Net Margin-216.74%
Debt/Equity1.49
Current Ratio1.79

Annual Financials (USD)

Metric20202021202220232024
Revenue$12.0M$28.0M$210.0M$222.0M$981.0M
Operating Profit$-664.0M$-870.0M$-850.0M$-873.0M$-370.0M
Net Profit$-678.0M$-782.0M$-883.0M$-926.0M$-405.0M
EPS$-12.56$-12.28$-13.40$-13.12$-1.34
Op Margin-5332.9%-3116.6%-405.2%-393.1%-37.7%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$1.7B$2.9B$2.8B$2.5B$2.6B
Total Liabilities$884.0M$1.7B$2.4B$2.4B$2.3B
Cash$1.0B$1.7B$1.5B$1.1B$1.2B
Borrowings$530.0M$1.1B$1.8B$1.8B$1.7B

Latest News

Hazardous Canadian wildfire smoke choking millions in US AFP · Jul 16, 2026 JPMorgan has blunt response to MicroStrategy's cash reserve boost TheStreet · Jul 16, 2026 Why Newell Brands Stock Raced More Than 5% Higher Today Motley Fool · Jul 16, 2026 Erbil’s Oldest Quarter Becomes Home to the Kurdistan Region’s First Cultural District GlobeNewswire · Jul 16, 2026 A boutique AI cloud provider is bringing the direct listing back Pitchbook · Jul 16, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-610.0M$-605.0M$-654.0M$-726.0M$-111.0M
Investing Cash Flow$-359.0M$-903.0M$-622.0M$-35.0M$-387.0M
Financing Cash Flow$-19.0M$-68.0M$-77.0M$-88.0M$-74.0M
Net Cash Flow$281.0M$687.0M$-361.0M$-308.0M$-145.0M
Free Cash Flow$-861.0M$-1.0B$-891.0M$-783.0M$-136.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.05
EV / EBITDA-10.96
FCF Yield-9.76%
Quick Ratio1.77
Interest Coverage-46.34
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATYR $0.49 +1.19% -0.72 $47.62M 0.00%
BCYPBig Cypress Acquisition Corp. $8.44 -19.23% 19.63 $425.36M 0.00%
CYTCyteir Therapeutics, Inc. $3.02 -2.27% -2.42 $108.71M 0.00%
DBTXDecibel Therapeutics, Inc. $4.91 -0.81% -1.95 $123.37M 0.00%
GRAYGraybug Vision, Inc. $5.50 -10.80% -4.23 $120.98M 0.00%

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapeutic solutions for various cancers, chronic hepatitis B virus (HBV) infection, and age-related conditions, primarily within Mainland China. Its flagship product candidate, HQP1351, is a BCR-ABL inhibitor specifically designed to target BCR-ABL1 mutants, notably those harboring the T315I mutation. The company's extensive pipeline further comprises: APG-2575, an orally administered, selective Bcl-2 inhibitor for hematologic malignancies and solid tumors. APG-115, an oral small-molecule inhibitor of MDM2-p53 protein-protein interactions, aimed at treating solid tumors and hematological cancers. APG-1252, a small-molecule drug engineered to restore apoptosis through dual inhibition of Bcl-2 and Bcl-xL proteins, indicated for small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. APG-2449, an oral inhibitor targeting FAK, ROS1, and ALK kinases. APG-5918, an orally available and selective embryonic ectoderm development inhibitor. APG-265, an MDM2 protein degrader. UBX1967/1325, which are also Bcl-2 inhibitors. Beyond its pharmaceutical development, Ascentage Pharma's operations encompass medical research and development, clinical trial management and execution, venture capital investments, rental services, and the promotion of science and technology. The company cultivates collaborative partnerships with various biotechnology and pharmaceutical enterprises, as well as academic research institutions. Established in 2009, Ascentage Pharma Group International is headquartered in Suzhou, China.

Ascentage Pharma Group International is headquartered in CN.

Ascentage Pharma Group International (AAPGV) stock trades at $17.38 with a market capitalization of $127.31M. The stock is valued at a price-to-earnings (P/E) ratio of -9.87, price-to-book of 9.54, price-to-sales of 22.36. Over the past 52 weeks the stock has ranged between $16.50 and $18.00, and currently trades 3.4% below its 52-week high.

On profitability, Ascentage Pharma Group International generates a return on equity (ROE) of -123.61%, return on capital employed of -51.46%, an operating margin of -210.42%, a net profit margin of -216.74%.

Official website: www.ascentage.cn

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides